Chagas disease, once restricted mainly to the Americas, Chagas disease has become a global health problem due to migration from endemic to non-endemic areas. In non-endemic regions, transmission is limited to vertical transmission from infected mothers to newborns or through blood and organ donations. A major challenge in the management of the disease lies in the diagnosis of chronic cases, as blood-borne parasites are often absent and antibodies persist for life, complicating the evaluation of treatment. This study investigates whether detection of circulating extracellular vesicles (EVs) or their immunocomplexes with host IgGs in the serum of chronic patients with Chagas disease could serve as diagnostic tools and biomarkers of the active presence of the parasite. This method may prove valuable in cases where parasitaemia and other diagnostic tests are inconclusive, especially for assessing treatment efficacy and confirming mother-to-child transmission. Together with exovesicle purification by ultracentrifugation, which is the ‘gold standard’, an affordable and simplified method for the isolation of EVs or immunocomplexes was tested for use in less well-equipped diagnostic laboratories. EV detection was performed by enzyme-linked immunosorbent assay (ELISA) targeting Trypanosoma cruzi antigens. Positive results were demonstrated in Bolivian patients in Spain, covering asymptomatic and symptomatic cases (cardiac, gastrointestinal or both). The study also examined infected mothers and their newborns. These findings were further confirmed in Panamanian patients with inconclusive diagnostic results. Moreover, host IgG isotypes that formed immunocomplexes with parasite exovsicles were identified, with IgG2 and IgG4 being predominant. Our results confirm the usefulness of circulating EVs and their immunocomplexes as markers of metabolically active T. cruzi in chronic infections without detectable parasitaemia, as well as their efficacy in confirming vertical transmission and in cases of inconclusive diagnostic tests. Chagas disease (CD), or American trypanosomiasis, is considered by the WHO as one of the most important neglected diseases of the American continent, considered as strictly American, there are currently cases of the disease spread all over the world as a consequence of human movements even in areas where the biological cycle of the protozoan parasite responsible for the disease does not occur. Laboratory diagnostic methods vary between direct tests that denote active parasitemia in blood in the acute phase of the disease and indirect molecular methods applied when the circulating parasitemia disappears in the chronic phase of the disease. Despite the existence of numerous diagnostic, molecular or immunological tests, the latter being generally easier to perform in diagnostic laboratories, the presence of the parasite always remains in doubt in various situations. Particularly in those patients after treatment since the presence of antibodies to the parasite remain at high titres for years, or in the case of newborn diagnosis in which the mother’s IgG makes specific immunological tests impossible for months. Therefore, given the need to find biomarkers in chronically ill patients or in mothers and newborns that indicate the active presence of parasites, we have used the purification of parasite extracellular vesicles (EVs) in circulating blood or the immunocomplexes they form with host IgGs, by means of two techniques, the gold standard technique by ultracentrifugation and an adapted technique, easier to apply in diagnostic laboratories, to purify these EVs in order to study the recognition of these EVs by antibodies against the parasite or against specific antigens of Trypanosoma cruzi specific antigens. We believe that this technique can be used when it is necessary to evaluate the efficacy of treatments or in neonatal diagnosis.